Detection of BRCA2 Receptor Gene Polymorphism in Sudanese Patients of Prostate Cancer in Khartoum State
Issue: 2023 - Volume 6 [Issue 1]
Jumaa Abuajila Salem Salama
Department of Biochemistry, College of Medicine, University of Zawia, Libya.
Tarig A. M. Hamid *
Department of Hematology and Immunohematology, Sharq Elnile College, Khartoum North, Sudan and Department of Hematology and Immunohematology, College of Medical Laboratory Science, Karary University, Khartoum, Sudan.
Dawelbiet Abdelaal Yahia
Department of Hematology and Immunohematology, College of Medical Laboratory Science, Karary University, Khartoum, Sudan.
Mohamed Maysara Ali
Department of Biochemistry, College of Medicine, University of El Imam El Mahdi, Sudan.
*Author to whom correspondence should be addressed.
Back Ground: Prostate cancer (PCa) is a genetically complex disease with multiple predisposing factors affecting presentation, progression, and outcome. This was analytical case-control study conducted between January 2019 up to January 2021.
Objective: This study was aimed to investigate the effect of BRCA2 polymorphism in the etiology of prostate cancer among Sudanese patients.
Methods: The study population was selected as one hundred patients with prostate cancer as case group and thirty healthy individuals as control. A total of 5 ml EDTA anti-coagulated venous blood samples were obtained from prostate cancer patients that admitted for routine follow-up of chemotherapy treatment, for hormones and remain of blood samples were kept at liquid nitrogen until used for DNA extraction and genes polymorphisms at institute of tropical diseases of Khartoum.
Results: One hundred and thirty persons were included, 100 patients were men with prostate cancer as case group while thirty were healthy subjects as control with mean age of case was 67.41years. The result showed that (87%) of patients with wild type BRCA2 6174delT alteration and (13%) with mutant type. The mean result of testosterone level, Insulin G. F level, and PSA level in associated to BRCA2 6174delT was insignificant difference between patients with mutant and wild genotype (P. value= 0.91, 0.061, 0.449, respectively).
Conclusion: This study was concluded the most frequent prostate cancer patients (87%) with wild type BRCA2 6174delT and there was no significant correlation in testosterone level, Insulin G. F and PSA level when correlated to BRCA2 6174delT with different genotype.
Keywords: Genetic polymorphism of BRCA2, prostate cancer (PCa)-Sudan, cancer
How to Cite
Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992;89:3367–71.
Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 1999;2:9–15.
Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet. 2004;129C:65–73.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J. et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.
Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25: 5864–74.
Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans. 2006;34:633–45.
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–82.
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9.
Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 2010;6:e1000995.
Mohammed El Imam MA, Higazi NZ, Abuidris DO, Idris AA, Khalid KE, Omran M, et al. Prostate specific antigen versus digital rectal examination as screening for CA prostate in Sudanese patients. Sudanese J. Public Health. 2009;4:278–281.
Elaimam IM, Abdel Raof Sharfi E. Incidence of carcinoma of the prostate in patients with normal prostatic specific antigen following prostatectomy. Global J. Med. Res. 2013;13(3–1):1–6.
Hamad and AbuIdris. Risk factors for prostate cancer patients among Gezira state-central of Sudan. IIUM Engineering Journal, 2011;12(4):203-11.
Haala M. Gabra, Adbelgadir A Elmugadam, et al. Serum total prostatic specific antigen and prostatic acid phosphatase measurement discriminating prostate carcinoma from benign prostatic hyperplasia in Sudanese patients. International Journal of Pharmaceutical Science Invention. 2014; 3(1):36-40.
Ingle SP et al. Effciency of serum prostate specifc antigen levels in diagnosing prostatic enlargements. Journal of Clinical and Diagnostic Research. 2013;7(1): 82-84
Mitra A, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. British Journal of Cancer. 2008;98:502–507.
Andrea Gsur, et al. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 2002;23(10):1647–1651.
Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean American immigrants in the United States and native Koreans in South Korea. Cancer Control. 2007;14:78–85.
Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17(4):337-47.